Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Clinical trial NCT04207190 · COMPLETED
Trial details
- NCT number
- NCT04207190
- Sponsor
- Roswell Park Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-23
- Primary completion
- 2024-05-26
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.